All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
The National Medical Products Administration (NMPA) in China has granted approval to the investigational new drug (IND) application for CT103A, for the treatment of relapsed/refractory (R/R) multiple myeloma (MM).1
CT103A is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) which is found on the surface of myeloma plasma cells. It contains a fully-human BCMA antibody, designed to reduce the toxic side effects often induced by non-human constructs.2
CT103A uses a lentiviral vector containing a CAR construct with a fully human single-chain variable fragment (scFv), CD8a hinge and transmembrane, 4-1BB costimulatory- and CD3z activation- domains.1
The pilot clinical study (ChiCTR1800018137) was an open-label, single-center and single-arm trial in patients aged 18–70 with R/R plasma cell malignancies.3 The study was conducted at the Tongji Hospital of Tongji Medical College, Wuhan, CH.4
During the XVII International Myeloma Workshop in Boston, US, the clinical responses and pharmacokinetics of CT103A were presented;4
The authors of the study concluded CT103A could be a consolidative therapeutic agent for patients with RRMM based on the high ORR, quick response rate and lack of major adverse events.
The drug company responsible for the therapy are preparing for a phase Ib/II trial launch in China in patients with RRMM.2
Read more about CAR T in MM here.
Your opinion matters
CAR T-cell therapies in clinical development in China
An overview of current clinical trials in hematologic malignancies in China presented by Jianxiang Wang during the 2nd European CAR T Meeting, Sitges, ES
Monthly educational theme | CAR T in multiple myeloma
Throughout January and February, the Multiple Myeloma (MM) Hub will be focusing on a new educational topic of chimeric antigen receptor (CAR) T-cell therapy
Subscribe to get the best content related to multiple myeloma delivered to your inbox